Brentuximab vedotin for treating T-cell lymphoma

Published on 12 Jul 2022
Last Updated on 12 Jul 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Brentuximab vedotin 50 mg powder for infusion in line with its registered indications for treating:

  • Previously untreated CD30-positive peripheral T-cell lymphoma when used with cyclophosphamide, doxorubicin and prednisone;

  • Relapsed or refractory systemic anaplastic large cell lymphoma; and

  • CD30-positive cutaneous T-cell lymphoma, after at least one prior systemic therapy.

Subsidy status

Brentuximab vedotin 50 mg powder for infusion is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications with effect from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits are provided in the Annex.

Brentuximab for treating T-cell lymphoma (12 Jul 22) [PDF, 133 KB]

PES Brentuximab for T-cell lymphoma (Published 12 July 2022) [PDF, 96 KB]